iTP Biomedica Corporation (“integrated Transcriptomics for Personalized medicine”) is a Toronto-based company founded to commercialize unique technology developed at Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute (LTRI). This proprietary whole-genome technology platform is positioned to supersede other molecular approaches to diagnosis/prognosis that have recently been commercialized. Current tests depend on limited numbers of marker genes to predict the behaviour of complex diseases, and therefore are prone to false positive and false negative results. By contrast, iTP Biomedica delivers a functional readout of the entire human genome and its Next-Gen Transcriptomic platform, incorporating a fully-developed Quality System, efficiently handles massive bioinformatics data sets to allow rapid development and commercialization of exquisitely accurate tests for cancer and other diseases. iTP’s lead products are diagnostic/prognostics for bladder cancer progression (an unserved $400 MM market), with pipeline products for other cancers to follow. The company is also developing a portfolio of blood- and urine-based diagnostic tests as part of its R&D pipeline and is adept at co-diagnostics development.